Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1097/MOG.0000000000000352 http://scihub22266oqcxt.onion/10.1097/MOG.0000000000000352 C5646688!5646688!28257308     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\28257308.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Curr+Opin+Gastroenterol 2017 ; 33 (3): 149-57 Nephropedia Template TP {{tp|p=28257308|t=2017. Emerging pharmacologic therapies for primary sclerosing cholangitis |pdf=|usr=}}{{28257308}} gab.com Text Emerging pharmacologic therapies for primary sclerosing cholangitis JO: Curr Opin Gastroenterol http://www.kidney.de/pget.php?&tw=1&pmid=28257308 #FOAvip Purpose of review: The only currently approved treatment for primary sclerosing cholangitis (PSC) is liver transplantation, with a median time to transplant of 12?18 years after diagnosis. There are a number of emerging drugs that have the potential to meet this critically unmet need that will be summarized and discussed herein. Recent findings: Although the cause of PSC is unknown, there are a number of novel therapeutics under development. These drugs target presumed pathogenic mechanisms largely extrapolated from ex-vivo and in-vivo preclinical models, as well as translational observations. Summary: Future therapeutic strategies for PSC may include a multitude of complex pathogenic mechanisms encompassing pathways of immunomodulation, the microbiome and inflammation-related fibrosis. Twit Text FOAVip Emerging pharmacologic therapies for primary sclerosing cholangitis ????Curr Opin Gastroenterol http://www.kidney.de/pget.php?&tw=1&pmid=28257308 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28257308 #FOAvip English Wikipedia <ref>{{Cite pmid|28257308}}</ref> Emerging pharmacologic therapies for primary sclerosing cholangitis #MMPMID28257308 Cheung AC; Lazaridis KN; LaRusso NF; Gores GJ Curr Opin Gastroenterol 2017[May]; 33 (3): 149-57 PMID28257308show ga Purpose of review: The only currently approved treatment for primary sclerosing cholangitis (PSC) is liver transplantation, with a median time to transplant of 12?18 years after diagnosis. There are a number of emerging drugs that have the potential to meet this critically unmet need that will be summarized and discussed herein. Recent findings: Although the cause of PSC is unknown, there are a number of novel therapeutics under development. These drugs target presumed pathogenic mechanisms largely extrapolated from ex-vivo and in-vivo preclinical models, as well as translational observations. Summary: Future therapeutic strategies for PSC may include a multitude of complex pathogenic mechanisms encompassing pathways of immunomodulation, the microbiome and inflammation-related fibrosis. äEmerging pharmacologic therapies for primary sclerosing cholangitis (epmc).pdf DeepDyve Pubget Overpricing